Drugs / anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)
anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00610311 | Jan 2008 → Feb 2011 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00610311 ↗ |
| Modality | Cell therapy | “TCR gene-engineered lymphocytes” NCT00610311 ↗ |
| Route | Intravenous | “anti-gp100:154-162 TCR engineered PBL by intravenous infusion” NCT00610311 ↗ |